Supplementary Table 1 - Main characteristics of studies on oral tofacitinib and ruxolitinib for the treatment of alopecia areata

Published: 12 August 2019| Version 1 | DOI: 10.17632/zc8k7phcng.1
Contributor:
Da-Ae Yu

Description

Supplementary table for the publication by Yu DA et al. Oral Janus kinase inhibitors for the treatment of alopecia areata: a systematic review and meta-analysis. J Am Acad Dermatol 2019.

Files